BioNTech has reported a sharp decline in revenue in H1 2023, generating only €1.44bn ($1.59bn) in the six months compared to €9.57 bn($10.5bn) it generated in the comparative period in 2022. Image Credit: ImageFlow ? Shutterstock.
The ADC is currently being investigated for safety and efficacy in an open-label, non-randomised Phase I/II trial (NCT05438329) for the treatment of advanced solid tumours.
BioNTech has reported a sharp decline in revenue in H1 2023, generating only €1.44bn ($1.59bn) in the six months compared to €9.57bn ($10.5bn) generated in the comparative period in 2022. This was mainly attributed to the decline in Covid-19 vaccineCovid-19 vaccine sales compared to last year. BioNTech’s market cap currently stands at $25.66bn.
Despite declining Covid-19 vaccineCovid-19 vaccine sales, the German-based company recently announced a $3.2bn contract with the US Government to supply its Omicron-adapted Covid-19 vaccines, developed in conjunction with Pfizer. The contract is contingent on FDA approval of the vaccine.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.